GHTC Innovating for Impact 2022 Partnership Award
Channel: GHTC
Date: 06/12/2022

Tuberculosis (TB) is the world's deadliest infectious disease, killing 1.6 million people each year. Drug-resistant tuberculosis (DR-TB) is a major contributor to the emerging crisis of antimicrobial resistance, with about 450,000 cases each year. Traditionally, treatment for DR-TB has been incredibly lengthy, complex, costly, and toxic. Individuals suffering from DR-TB typically had to take up to 20 or more pills a day—as many as 14,000 total over the course of 18 months or more of treatment. These medications were often accompanied by terrible side effects, such as hearing loss. Still, among those people who were able to access treatment, nearly half went uncured. 

TB Alliance, a nonprofit product development partnership that works with a global constellation of funders, research partners, and community stakeholders, developed the novel drug pretomanid, a much-needed advance in DR-TB therapy. Pretomanid has been approved by more than 20 regulatory agencies and procured by more than 40 countries around the world as part of the six-month, all-oral "BPaL" regimen. In trials, BPaL cures 90 percent of patients in a fraction of the time and with fewer toxic side effects than traditional DR-TB therapy—a game changer in the fight against some of the deadliest forms of TB.